A drug made by Boehringer Ingelheim and Zealand Pharma helped people lose 16.6% of their body weight in a late-stage trial (a big test before the FDA decides whether to approve a medicine). This is positive news for the companies' weight-loss drug program.

• •Boehringer-Zealand drug delivered 16.6% weight loss in late-stage trial
• •Trial is Phase 3 (pre-FDA decision stage)

Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Eli Lilly's retatrutide, a next-generation weight-loss drug, has passed its first major late-stage trial (Phase 3 trial), which tests whether a drug actually works in patients. This is an important step toward getting the drug approved by regulators.

• •Retatrutide passed its first Phase 3 trial
• •Drug is positioned as Lilly's next-generation obesity therapy
• •Result advances retatrutide toward regulatory submission

Boehringer Ingelheim announced that survodutide, a dual-action drug that works like both glucagon and GLP-1 (weight-loss hormones), helped people lose 16.6% of their body weight in a Phase III trial (a large late-stage test). The drug also improved other health markers related to metabolism in people with obesity or excess weight.

• •Survodutide hit 16.6% weight loss in Phase III obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial showed metabolic improvements in obesity/overweight patients

• •Boehringer's dual-acting obesity shot met its endpoint in a Phase 3 trial

• •Boehringer's dual agonist hit 16.6% weight loss in phase 3
• •Phase 3 readout leaves key questions unanswered

Retatrutide, a new weight-loss drug, showed patients lost 28.7% of their body weight in testing. PatentVest says the company's next big challenge will be protecting its patents so competitors can't copy the drug.

• •Retatrutide produced 28.7% body weight loss in testing
• •PatentVest flags IP protection as the next competitive battleground

Boehringer Ingelheim's survodutide, a GLP-1 dual agonist (a type of weight-loss and diabetes drug), showed positive results in a large Phase 3 trial (a major test required before FDA approval). The company is advancing the drug toward regulatory approval based on these successful trial results.

• •Boehringer Ingelheim's survodutide hit positive results in a Phase 3 trial
• •Survodutide is a GLP-1/glucagon dual agonist for weight loss and diabetes
• •Company advancing the drug toward regulatory approval

Survodutide, a drug that works on two different body signals to reduce weight, showed strong results in a Phase 3 trial (a large test needed before the FDA considers approval). The trial tested whether survodutide could help people with obesity lose weight.

• •Survodutide met endpoints in a Phase 3 obesity trial
• •Drug is a dual agonist mechanism
• •Trial tested weight loss in patients with obesity

Tirzepatide (the drug in Mounjaro and Zepbound) reduced the risk of death from heart and blood vessel problems by 62% in a study. This finding suggests the weight-loss drug may protect people's hearts, not just help them lose weight.

• •Tirzepatide linked to 62% lower risk of cardiovascular death in study
• •Finding applies to Mounjaro and Zepbound, both tirzepatide brands

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in a Phase 3 trial (a late-stage test) that resembled Novo Nordisk's Wegovy (a popular weight-loss medicine). The comparison suggests the drug may be competitive in the weight-loss market.

• •Boehringer/Zealand obesity drug posted Phase 3 results compared to Novo's Wegovy
• •Trial profile described as 'more akin' to Wegovy

A cardiologist discussed how tirzepatide (a dual-action weight-loss and diabetes drug) performed better than dulaglutide (another diabetes drug) in protecting the heart and kidneys in a clinical study. The comparison highlights tirzepatide's broader benefits beyond weight loss.

• •Tirzepatide outperformed dulaglutide on cardiorenal outcomes in a clinical study
• •Steven Nissen, MD discussed the comparison in a Q&A format
• •Findings position tirzepatide's benefits beyond weight loss

Novo Nordisk released data on an oral (swallowed) form of semaglutide for children, which could open up a new market for GLP-1 drugs in younger patients. This expands the company's GLP-1 portfolio beyond adults.

• •Novo Nordisk released data on oral semaglutide in children
• •Data positions oral semaglutide for potential pediatric use

Novo Nordisk's oral form of semaglutide (Rybelsus) could become the first pill version of a GLP-1 drug for kids and teenagers with type 2 diabetes. The company is exploring whether the medicine works safely and effectively in younger patients.

• •Novo Nordisk evaluating oral semaglutide (Rybelsus) in children and adolescents with type 2 diabetes
• •Would be first oral GLP-1 RA therapy for pediatric T2D if successful

A partner company has moved a triple agonist peptide (a drug that works on three different receptors to reduce appetite and weight) that was originally developed by Gubra into Phase 2 testing (the second stage of human trials). The drug targets obesity, joining other similar medications in development.

• •Gubra-originated triple agonist obesity peptide advanced to Phase 2 by partner
• •Asset is a triple receptor agonist targeting obesity

Novo Nordisk is studying semaglutide (a weight-loss and diabetes drug) for alcohol-related issues and advancing trials of LX9851 (an experimental drug in development). Both moves expand the company's pipeline of potential new uses for its medicines.

• •Novo Nordisk studying semaglutide for alcohol-related issues
• •LX9851 trial advancing as part of pipeline expansion

• •Oral diabetes drug reported to show promise in children and adolescents
• •Source attributed to Novo Nordisk

Boehringer Ingelheim's retatrutide, a dual-action weight-loss drug, helped people lose up to 16.6% of their body weight in a trial. Retatrutide works on two hormones in the body to reduce hunger and help with obesity.

• •Boehringer Ingelheim's dual agonist drove up to 16.6% body weight loss in a trial
• •The drug acts on two hormones to reduce hunger and treat obesity

Novo Nordisk will show new study results about Wegovy (a GLP-1 weight-loss medicine) and its effects on women with obesity at a major European medical conference. The company will also discuss experimental next-generation weight-loss treatments.

• •Novo Nordisk to present Wegovy data at European Congress on Obesity
• •Presentations include new findings on women with obesity
• •Company will also discuss next-generation weight-loss candidates

Antag Therapeutics will show early data on AT7687, a new peptide drug it's developing to treat diabetes, at a major diabetes conference in 2026. The drug works by blocking a protein called GIPR and is the first of its kind in that category.

• •Antag Therapeutics to present AT7687 data at ADA 2026 Scientific Sessions
• •AT7687 is described as a first-in-class GIPR antagonist peptide
• •Program targets diabetes indication

• •Lexaria planning 18-arm study comparing pills and capsules across two GLP-1 drugs

• •Asahi Kasei initiated a Phase 1 trial of a peptide drug from PeptiDream

• •Asahi Kasei initiated a Phase 1 trial of a PeptiDream-derived peptide drug